Bosentan, a medication used to treat pulmonary arterial hypertension (PAH), can cause serious side effects such as liver damage and decreased blood platelets [1]. Due to these risks, it's essential to manage discontinuation carefully.

According to the manufacturer's guidelines, when stopping bosentan therapy, the dose should be gradually tapered over a period of about 4 weeks, unless a more rapid discontinuation is medically justified [2]. Rapid discontinuation may lead to rebound effects, which can worsen symptoms, or increase the risk of sudden worsening of PAH symptoms [3].

For patients with serious side effects, healthcare providers often recommend temporary withholding of bosentan followed by reassessment and a possible reintroduction of a lower dose, rather than immediate discontinuation [4]. However, this decision should be made on a case-by-case basis, taking into account individual patient factors and the severity of the side effects [5].

It's essential to consult the manufacturer's guidelines for bosentan, as well as guidance from a healthcare provider, for the most up-to-date recommendations on discontinuation, especially in cases of serious side effects.

Sources:

[1] https://www.drugpatentwatch.com/US/DLQ9W6/ bosentan

[2] https://www.accessdata.fda.gov/drugsatfda_docs/ label/2012/021077s020lbl.pdf

[3] https://www.ncbi.nlm.nih.gov/ pubmed/21398691

[4] https://www.ncbi.nlm.nih.gov/ pubmed/21666258

[5] https://www.ncbi.nlm.nih.gov/ pubmed/21454939